Axxcess Wealth Management LLC Acquires 1,506 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Axxcess Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,333 shares of the medical research company’s stock after purchasing an additional 1,506 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $12,385,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of TMO. Power Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $1,392,000. Malaga Cove Capital LLC lifted its stake in shares of Thermo Fisher Scientific by 37.8% in the 4th quarter. Malaga Cove Capital LLC now owns 1,091 shares of the medical research company’s stock valued at $579,000 after purchasing an additional 299 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in Thermo Fisher Scientific by 12.6% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 11,459 shares of the medical research company’s stock valued at $6,082,000 after purchasing an additional 1,279 shares during the last quarter. Aveo Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock valued at $433,000 after buying an additional 72 shares in the last quarter. Finally, Accretive Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 8.1% in the 4th quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock valued at $340,000 after buying an additional 48 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,277 shares of company stock valued at $35,373,364. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $1.13 during midday trading on Friday, hitting $572.38. The company had a trading volume of 1,749,670 shares, compared to its average volume of 1,409,187. The company has a fifty day simple moving average of $575.39 and a 200 day simple moving average of $532.82. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock has a market cap of $218.48 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Finally, Evercore ISI raised their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.